Scientists in Australia have made an important discovery that may help explain why some people lose their eyesight much faster than others as they grow older.
The research focuses on age-related macular degeneration, or AMD, a disease that damages the retina and slowly steals central vision from millions of older adults around the world.
The study was led by researchers from the University of Melbourne, the Center for Eye Research Australia, and the Garvan Institute of Medical Research.
Their findings were published in the journal Genome Medicine and are already helping scientists better understand how AMD develops inside the eye.
AMD mainly affects people over the age of 50. The disease damages the macula, the part of the retina responsible for sharp central vision.
This area is essential for reading, driving, watching television, and recognizing faces. As the disease progresses, many people begin to notice blurry or distorted vision. In severe cases, central sight can become almost completely lost.
Although AMD rarely causes total blindness, it can seriously reduce quality of life and independence. Many people with advanced AMD struggle with daily tasks and may lose confidence living alone.
Doctors have known for years that AMD does not behave the same way in every patient. Some people experience slow changes over decades, while others suddenly develop aggressive forms of the disease that lead to rapid vision loss. Scientists have long suspected that hidden biological differences may explain why this happens.
The new research provides some of the clearest evidence yet that different forms of AMD may actually be different diseases at the molecular level.
The scientists focused on patients with a retinal feature called reticular pseudodrusen. These are tiny deposits that appear under the retina during eye examinations.
Previous studies showed that people with these deposits are more likely to develop severe AMD and permanent vision damage, but researchers did not fully understand why.
To investigate, the research team collected small skin samples from more than 100 Australians diagnosed with AMD. Some had reticular pseudodrusen while others did not.
The scientists then used stem cell methods to reprogram the skin cells into retinal cells in the laboratory. This allowed them to create living models of the patients’ eye cells and study how they functioned.
By comparing the cells from different patients, researchers discovered major differences in the activity of genes and proteins. They found that patients with reticular pseudodrusen showed changes linked to how cells maintain their structure and stability.
Professor Alice Pébay, one of the lead researchers from Melbourne Medical School and the School of Biomedical Sciences, said the study showed that AMD patients with reticular pseudodrusen appear to have distinct biology compared with the more common form of AMD.
The discovery is important because current AMD treatments are limited. Existing medicines can sometimes slow disease progression, especially in wet AMD, but they usually cannot restore lost vision. In addition, some patients benefit much more than others.
Professor Robyn Guymer from CERA explained that the findings may help scientists understand why certain treatments fail in some patients. If different forms of AMD involve different biological pathways, then patients may eventually require different medicines designed specifically for their form of disease.
This idea is part of a growing movement toward personalized medicine. Instead of giving every patient the same treatment, doctors try to understand the exact biological processes happening inside each person’s body.
Researchers believe this approach could eventually improve eye care dramatically. In the future, patients may receive tests that identify which type of AMD they have at the molecular level. Doctors could then select treatments most likely to work for that individual patient.
The study also shows the growing power of stem cell research in medicine. Turning skin cells into retinal cells gives scientists a rare opportunity to study human eye disease in detail. Because retinal tissue is difficult to obtain directly from patients, this technology provides an important new research tool.
The findings may also help future scientists develop treatments before major vision loss occurs. If doctors can identify high-risk patients earlier, they may be able to intervene before the retina becomes badly damaged.
The research appears carefully designed and provides valuable new information about severe AMD. Still, experts caution that more work is needed before the findings can directly change patient care.
Scientists must now confirm the results in larger studies and determine which biological pathways are the most important targets for future medicines.
Even so, the discovery represents an exciting step forward. AMD affects hundreds of millions of people globally, and there is still no cure. Better understanding the hidden biological differences between patients could help researchers develop safer, more effective, and more personalized treatments in the years ahead.
The study also reminds us that diseases that appear similar on the surface may actually work very differently inside the body. By uncovering these hidden differences, scientists move closer to protecting vision and improving quality of life for aging populations worldwide.
If you care about health, please read studies that vitamin D can help reduce inflammation, and vitamin K could lower your heart disease risk by a third.
For more health information, please see recent studies about new way to halt excessive inflammation, and results showing foods that could cause inflammation.
